CN108236714B - Composition for relieving physical fatigue and assisting in reducing blood fat and soft capsule thereof - Google Patents

Composition for relieving physical fatigue and assisting in reducing blood fat and soft capsule thereof Download PDF

Info

Publication number
CN108236714B
CN108236714B CN201810085469.8A CN201810085469A CN108236714B CN 108236714 B CN108236714 B CN 108236714B CN 201810085469 A CN201810085469 A CN 201810085469A CN 108236714 B CN108236714 B CN 108236714B
Authority
CN
China
Prior art keywords
parts
soft capsule
coenzyme
oil
assisting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810085469.8A
Other languages
Chinese (zh)
Other versions
CN108236714A (en
Inventor
石文文
张芙蓉
赵伏梅
张劲松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JIANGSU SHENHUA PHARMACEUTICAL CO Ltd
Original Assignee
JIANGSU SHENHUA PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JIANGSU SHENHUA PHARMACEUTICAL CO Ltd filed Critical JIANGSU SHENHUA PHARMACEUTICAL CO Ltd
Priority to CN201810085469.8A priority Critical patent/CN108236714B/en
Publication of CN108236714A publication Critical patent/CN108236714A/en
Application granted granted Critical
Publication of CN108236714B publication Critical patent/CN108236714B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/185—Vegetable proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/535—Perilla (beefsteak plant)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention discloses a composition for relieving physical fatigue and assisting in reducing blood fat and a soft capsule thereof, wherein the composition comprises coenzyme Q10The weight ratio of the buckwheat protein to the perilla seed oil is 30-50: 10-20: 5 to 8. The preparation method of the soft capsule comprises the following steps: mixing gelatin, glycerol, purified water, titanium dioxide and cocoa shell color to prepare a glue solution; then preparing oil wax solution from soybean oil and beeswax, adding coenzyme Q10Adding oil wax solution into buckwheat protein and perilla seed oil, grinding with colloid mill, vacuum-pumping under reduced pressure for degassing to obtain filling liquid, and making into soft capsule with the filling liquid and colloid solution by pill press. The coenzyme Q of the invention10The compound soft capsule has good safety, good health care effect, high quality and simple preparation method, and is suitable for popularization and application.

Description

Composition for relieving physical fatigue and assisting in reducing blood fat and soft capsule thereof
Technical Field
The invention relates to a coenzyme Q-containing food10The health food or the medicine, in particular to a coenzyme Q-containing food or medicine for relieving physical fatigue and assisting in reducing blood fat10The composition or the compound soft capsule and the preparation method thereof.
Background
Physical fatigue which cannot be eliminated even after sufficient sleep is common in fast-paced and high-efficiency life at present, and is mainly characterized by slow persistence or repeated attacks, which is called chronic fatigue syndrome.
The data show that the incidence of chronic fatigue syndrome is on an increasing trend worldwide. In the uk and the usa 20%, 14% of men and 25%, 20% of women, respectively, feel fatigue overall; in China, chronic fatigue of overweight people is particularly prominent in the white-collar class of over 40 years old. Chronic fatigue syndrome is frequently occurred in younger people with higher socioeconomic status, and the incidence rate of medical staff, particularly nurses, is higher than that of general people. According to the diagnostic criteria established by the American center for disease control, there are the following clinical manifestations: (1) persistent or recurrent fatigue, which is often caused by excessive physical or psychological stress and which cannot be eliminated after sufficient sleep, lasts for more than 6 months. (2) Muscle weakness of unknown cause. (3) Insomnia, dreaminess and early awakening. (4) Dizziness, fullness of head, and headache. (5) The memory is reduced and the attention is not easy to concentrate. (6) Loss of appetite. (7) Chest tightness, discomfort or pain in the shoulder, back and waist, and delocalized myalgia and arthralgia. (8) Depressed mood, anxiety or stress fear. (9) Interest declines or is lost. (10) Sexual function declines. (11) Low heat. (12) Dry throat, sore throat or tightness in the throat, pharyngeal congestion was examined without clear tonsillitis. (13) Enlarged or tender lymph nodes are accessible at the neck. The patient can be diagnosed with chronic fatigue syndrome only if the patient has 8 of the above symptoms. In patients with chronic fatigue syndrome, a considerable proportion of patients develop symptoms of elevated blood lipid levels.
The key point of preventing chronic fatigue syndrome is to emphasize scientific and reasonable life style and optimistic breast-conception, correctly treat and treat various adverse factors, and need to be treated with medicines under the guidance of doctors when necessary. At present, no medicine or health-care food which has good safety and stable quality and can simultaneously effectively relieve physical fatigue and assist in reducing blood fat exists.
Disclosure of Invention
The invention aims to provide the coenzyme Q-containing food which has good safety, good health-care effect, high quality, convenient eating and the effects of relieving physical fatigue and assisting in reducing blood fat10A preparation method of a compound soft capsule.
The purpose of the invention is realized by the following modes:
a composition for relieving physical fatigue and reducing blood lipid, the composition comprises coenzyme Q10The weight ratio of the buckwheat protein to the perilla seed oil is 30-50: 10-20: 5 to 8.
Coenzyme Q in the above composition10The weight ratio of the buckwheat protein to the perilla seed oil is 37:15: 6.
The composition can be made into oral preparation with adjuvants.
The oral preparation is soft capsule, hard capsule, granule, tablet, pill or oral liquid.
The soft capsule for relieving physical fatigue and assisting in reducing blood fat comprises filling liquid and a rubber sheet, wherein the filling liquid is prepared from the following components in parts by weight:
coenzyme Q1030-50 parts of buckwheat protein, 10-20 parts of perilla seed oil, 300-500 parts of soybean oil and 25-40 parts of beeswax;
the rubber is prepared from the following components in parts by weight:
1-4 parts of cocoa shell color, 1-4 parts of titanium dioxide, 180-220 parts of gelatin, 60-90 parts of glycerol and 180-220 parts of purified water.
The soft capsule is preferably prepared from the following components in parts by weight:
coenzyme Q1037 parts of buckwheat protein, 6 parts of perilla seed oil, 397 parts of soybean oil, 30 parts of beeswax, 2 parts of cocoa shell color, 2 parts of titanium dioxide, 200 parts of gelatin, 80 parts of glycerol and 200 parts of purified water.
The preparation method of the soft capsule for relieving physical fatigue and assisting in reducing blood fat comprises the following steps:
mixing gelatin, glycerol, purified water, titanium dioxide and cocoa shell color to prepare a glue solution; then preparing oil wax solution from soybean oil and beeswax, adding coenzyme Q10Adding oil wax solution into buckwheat protein and perilla seed oil, grinding with colloid mill, vacuum-pumping under reduced pressure for degassing to obtain filling liquid, and making into soft capsule with the filling liquid and colloid solution by pill press.
The soft capsule is prepared by shaping, washing, drying, and selecting.
The specific steps for preparing the oil wax liquid are as follows: weighing soybean oil, heating to 60-70 ℃, adding beeswax, keeping the temperature at 60-70 ℃, completely melting the beeswax, and uniformly stirring and mixing to obtain an oil wax liquid;
the conditions for the above compressed soft capsules were as follows: the temperature of the glue box is 50-60 ℃, the temperature of the heat preservation tank is 35-45 ℃, and the temperature of the spray body is 31-41 ℃.
The composition can be applied to preparation of medicines or health-care foods for relieving physical fatigue and assisting in reducing blood fat.
The above coenzyme Q10The preparation method of the compound soft capsule specifically comprises the following steps:
preparation of glue solution: mixing gelatin, glycerol, purified water, titanium dioxide, and cocoa shell color under stirring to dissolve gelatin completely, and removing bubbles under vacuum degree of 0.08 MPa. Filtering the glue solution, and storing at 50-60 ℃ for later use;
preparing oil wax liquid: accurately weighing soybean oil according to a formula, placing the soybean oil in a mixing tank, heating the soybean oil to 60-70 ℃, adding beeswax, keeping the temperature at 60-70 ℃, completely melting the beeswax, and uniformly stirring and mixing to obtain oil wax liquid, wherein the oil wax liquid is stored at 40-50 ℃ for later use;
preparing filling liquid: accurately weighing a specified amount of coenzyme Q10Adding buckwheat protein and perilla seed oil into the oil wax liquid, and stirring for 30min to uniformly mix the materials. Then passing through a colloid mill for 3 times; vacuum pumping (vacuum degree-0.08 MPa), removing gas in the material to obtain filling liquid;
fourthly, pelleting: adding the mixed filling liquid into a pelleting machine, controlling the temperature of a capsule box to be 55 +/-5 ℃, the temperature of a heat-preservation tank to be 40 +/-5 ℃, the temperature of a spray body to be 36 +/-5 ℃, and utilizing a glue solution to press soft capsules;
shaping: drying with 18-26 deg.C cold air for 4 hr (relative humidity of 30% -40%), and shaping the soft capsule.
Sixthly, washing pills: the soft capsule is washed with 95% edible alcohol to remove surface oil.
And (c) drying: drying for 24 hours (relative humidity is 20-30%) at 20-28 DEG C
Eighthly, selecting the pills: selecting the normal-shape pills, and removing the non-plastic pills. Removing big pill, opposite sex pill, shriveled pill, etc. by manual pill picking;
the invention utilizes the colloid mill to fully grind the filling liquid, thereby ensuring the uniformity, fineness and stability of the content.
Coenzyme Q10(Coenzyme Q10) Ubiquinone and decene quinone, which are also known as quinone compounds, are present in most cells of living organisms. The chemical name is as follows: 2- (3,7,11,15,19,23,27,31,35, 39-decamethyl-2, 6,10,14,18,22,26,30,34, 38-forty-carbon decaalkenyl) -5, 6-dimethoxy-3-methyl-p-benzoquinone. Coenzyme Q10Coenzyme Q was first discovered and isolated in bovine heart mitochondria by professor Frederick Crane, USA, 195710. The method realizes the synthesis and production of coenzyme Q by extracting solanesol from tobacco leaves as raw materials in Japan in the early stage of the eighties of the twentieth century10To coenzyme Q10The cost is greatly reduced, which is applied to coenzyme Q10The application, popularization and popularization of the method play an important promoting role. In 2005, S Ken et al found that coenzyme Q was synthesized in vivo in normal persons 30-40 years old10The ability of the composition to take high doses of coenzyme Q from food is also gradually reduced10Supplementing its deficiency. Thereafter coenzyme Q10Is greatly valued in the industry as a nutritional health product.
Coenzyme Q10Is a fat-soluble vitamin-like substance and widely exists on cell mitochondria of animals, plants, microorganisms and the like. It is combined with mitochondrion inner membrane, is an important hydrogen transfer body in respiratory chain, is an effective biochemical drug, has important physiological action, and is a natural antioxidant produced by cell itself. Coenzyme Q10Can improve the activity of superoxide dismutase SOD in blood serum, reduce the content of malondialdehyde MDA in blood serum, maintain the integrity of cells, and prevent the leakage of intracellular enzymes by eliminating peroxy radicals generated by movement in vivo, thereby delaying the generation of fatigue and being beneficial to the elimination of the fatigue after movement.
The buckwheat grains are rich in protein, fat, starch, minerals, vitamins and abundant bioflavonoids. Buckwheat protein is the main nutrient component of buckwheat. The buckwheat protein has high biological value, reasonable amino acid composition and is rich in 8 essential amino acids for human body. The ratio of lysine to arginine in dietary protein determines plasma cholesterol levels, and glycine content also has an effect on cholesterol reduction. Amino acid analysis of buckwheat protein shows that it has a low lysine to arginine ratio, a higher glycine content than soy protein, and that buckwheat protein contains some lipids and may have cholesterol-lowering effect.
The perilla seed oil is edible oil extracted from perilla seeds. Perilla oil can control platelet aggregation in human body, reduce neutral lipid in blood, remove cholesterol, and prevent thrombosis. Scientific experiments prove that the plant oil with the highest alpha-linolenic acid content in the currently known plant oils is entitled 'deep sea fish oil on land'.
Compared with the prior art, the invention has the beneficial effects that: the invention uses coenzyme Q10The buckwheat protein and the perilla seed oil are organically combined, so that the dual effects of relieving physical fatigue and assisting in reducing blood fat can be realized. Long-term stability research shows that various indexes of the coenzyme Q10 composite soft capsule meet the regulations after being stored for 6 months under long-term conditions, and the formula process is reliable, and the prepared agent has stable quality.
The specific implementation mode is as follows:
the invention is further illustrated by the following specific examples. However, the specific details of the embodiments are merely for explaining the present invention and should not be construed as limiting the general technical solution of the present invention. Coenzyme Q in the examples10From Fufeng group GmbH, Perilla seed oil from Gannan Natural flavor oil GmbH, Jiangxi province, Cera flava from eastern bees wax glue industry GmbH, and titanium dioxide from Shanghai titanium white chemical products GmbH. The buckwheat protein is prepared from buckwheat by conventional vegetable protein alkali extraction and acid precipitation method, and has crude protein content of more than 30%.
Example 1
(I) screening and optimization of prescriptions
1. The amount of diluent used
The diluent is selected in a reasonable proportion, so that the liquidity of the liquid medicine is ensured, and the filling of the soft capsule is facilitated; on the other hand, the viscosity of the mixed liquid is ensured to be proper, and the stability of the mixed liquid is ensured. The dosage of the diluent is considered in the experiment, the raw material extract and the diluent are mixed according to different proportions, stirred evenly, ground on a colloid mill for 30min, and the uniformity and the stability of the medicine mixed liquid after the diluent with different proportions is added are respectively observed.
Taking 1 time of prescription amount of raw materials (45 g): comprising a coenzyme Q10(28.71g), buckwheat protein (11.64g) and perilla seed oil (4.65g), wherein 4 parts of the mixture are respectively added with a mixture matrix of 3 times, 5 times, 7 times and 9 times of the raw materials of soybean oil and beewax, and the mixture matrix is uniformly mixed, and the results are shown in the following table 1.
TABLE 1 selection test results for diluent dosage
Figure BDA0001562278520000051
And (4) conclusion: if the diluent is too small, the liquid medicine is sticky and has poor fluidity, and the phenomenon of nozzle blockage easily occurs in the filling process of the soft capsule, so that the process is influenced. Therefore, according to the experiment, the ratio of the raw materials to the diluent is more than 1: 5.
2. Investigation of suspending agent
In order to ensure the quality of the product, beeswax is selected as a suspending agent through a large number of preliminary experiments, the dosage proportion of the suspending agent is investigated, and the specific method is as follows:
taking 0.5 time of the prescription amount of raw materials: comprising a coenzyme Q104 parts of buckwheat protein and perilla seed oil (37:15:6) are respectively added with 8g, 12g, 16g and 20g of beeswax, and the total amount of soybean oil is increased to 200 g. Dissolving beeswax in soybean oil, cooling to room temperature, adding 0.5 times of the formula amount of raw materials, mixing uniformly, and grinding for 30 minutes by a colloid mill. 20g of each content was taken out and placed in a centrifuge tube having the same diameter, and centrifuged at 500rpm for 30 minutes. Whether the liquid medicine is layered or not is observed, and the result is shown in table 2.
TABLE 2 results of different suspending agent dosages
Figure BDA0001562278520000052
And (4) conclusion: the results show that 6-10% (based on coenzyme Q) is added10The total weight of the buckwheat protein, the perilla seed oil, the soybean oil and the beewax is 100 percent) is taken as a suspending agent to achieve better effect, so that the beewax with the content of about 6 percent is optimally selected and added into the product.
Example 2
The formula is as follows: coenzyme Q1037 parts by weight, 15 parts by weight of buckwheat protein, 6 parts by weight of perilla seed oil, 397 parts by weight of soybean oil, 30 parts by weight of beeswax, 2 parts by weight of cocoa shell color, 2 parts by weight of titanium dioxide, 200 parts by weight of gelatin, 80 parts by weight of glycerol and 200 parts by weight of purified water.
The preparation method comprises the following steps:
preparation of glue solution: mixing and stirring gelatin, glycerol, purified water, titanium dioxide and cocoa shell color to completely dissolve the gelatin, removing bubbles under the condition of a vacuum degree of 0.08MPa, filtering to obtain a glue solution, and storing at 50-60 ℃ for later use;
preparing oil wax liquid: accurately weighing soybean oil according to a formula, placing the soybean oil in a mixing tank, heating the soybean oil to 70 ℃, adding beeswax, keeping the temperature at 60-70 ℃ to completely melt the beeswax, and uniformly stirring and mixing to obtain oil wax liquid, wherein the oil wax liquid is stored at 40-50 ℃ for later use;
preparing filling liquid: accurately weighing a specified amount of coenzyme Q10Adding buckwheat protein and perilla seed oil into the oil wax liquid, and stirring for 30min to uniformly mix the materials; then passing through a colloid mill for 3 times; vacuum pumping (vacuum degree-0.08 MPa), removing gas in the material to obtain filling liquid;
fourthly, pelleting: adding the mixed filling liquid into a pelleting machine, controlling the temperature of a capsule box to be 55 +/-5 ℃, the temperature of a heat-preservation tank to be 40 +/-5 ℃, the temperature of a spray body to be 36 +/-5 ℃, and pressing soft capsules by using the glue liquid, wherein the weight of each content is controlled to be 0.40 g;
shaping: drying with 18-26 deg.C cold air for 4 hr (relative humidity of 30% -40%), and shaping the soft capsule.
Sixthly, washing pills: the soft capsule is washed with 95% edible alcohol to remove surface oil.
And (c) drying: drying for 24 hours (relative humidity is 20-30%) at 20-28 DEG C
Eighthly, selecting the pills: selecting the normal-shape pills, and removing the non-plastic pills. Removing large pills, special pills and shriveled pills by manual pill picking.
Example 3
The formula is as follows: coenzyme Q1045 parts of buckwheat protein, 18 parts of perilla seed oil, 8 parts of soybean oil, 300 parts of beewax, 3 parts of cocoa shell color, 3 parts of titanium dioxide, 180 parts of gelatin, 70 parts of glycerol and 190 parts of purified water.
The preparation method comprises the following steps:
preparation of glue solution: mixing and stirring gelatin, glycerol, purified water, titanium dioxide and cocoa shell color to completely dissolve the gelatin, removing bubbles under the condition of a vacuum degree of 0.08MPa, filtering to obtain a glue solution, and storing at 50-60 ℃ for later use;
preparing oil wax liquid: accurately weighing soybean oil according to a formula, placing the soybean oil in a mixing tank, heating the soybean oil to 70 ℃, adding beeswax, keeping the temperature at 60-70 ℃ to completely melt the beeswax, and uniformly stirring and mixing to obtain oil wax liquid, wherein the oil wax liquid is stored at 40-50 ℃ for later use;
preparing filling liquid: accurately weighing a specified amount of coenzyme Q10Adding buckwheat protein and perilla seed oil into the oil wax liquid, and stirring for 30min to uniformly mix the materials; then passing through a colloid mill for 3 times; vacuum pumping is carried out under reduced pressure (the vacuum degree is 0.08MPa), and gas in the materials is removed, so as to obtain filling liquid;
fourthly, pelleting: adding the mixed filling liquid into a pelleting machine, controlling the temperature of a capsule box to be 55 +/-5 ℃, the temperature of a heat-preservation tank to be 40 +/-5 ℃, the temperature of a spray body to be 36 +/-5 ℃, and pressing soft capsules by using the glue liquid, wherein the weight of each content is controlled to be 0.40 g;
shaping: drying with 18-26 deg.C cold air for 4 hr (relative humidity of 30% -40%), and shaping the soft capsule.
Sixthly, washing pills: the soft capsule is washed with 95% edible alcohol to remove surface oil.
And (c) drying: drying for 24 hours (relative humidity is 20-30%) at 20-28 DEG C
Eighthly, selecting the pills: selecting the normal-shape pills, and removing the non-plastic pills. Removing large pills, special pills and shriveled pills by manual pill picking.
Test example 1
1. Safety toxicology test
Test animals: SPF grade ICR mouse 20 (each half of male and female, weight 18.0 ~ 20.0g)
Selecting the dosage: example 2 Soft Capsule fill solution prepared 20.0g/kg BW
By adopting a maximum tolerated dose method, after fasting the mice for 16 hours, selecting 10 male and female mice according to the weight requirement, weighing, dyeing, orally intragastrically administering the test substances, and observing for 14 days after intragastrically administering. Observing whether the central nervous system and the body move to change postures, abnormal cry, tremor or abnormal movement and the like; whether the autonomic nervous system has pupil enlargement, salivation, lacrimation, etc.; whether the respiratory system has rhinorrhea, tidal breathing, etc. And the time to onset of toxic symptoms was recorded. If the animals died, the number of deaths, the time of death, and the body weight was weighed on day 14.
TABLE 3 acute toxicity test results in mice
Figure BDA0001562278520000071
Test example 2
1. Functional test for relieving physical fatigue
Test animals: the SPF grade outcrossing group comprises 200 male Kunming mice of 18-22 g, and the soft capsules prepared according to the example 2 are used in the example group.
Dose grouping and administration mode: the dose groups of examples, the sample solvent control group, and coenzyme Q were designed to be 20 times of the recommended dose (0.5g/60kg BW) for human body10Perilla seed oil, buckwheat protein group. And (3) administering the test sample in an intragastric manner, adjusting the intragastric volume of the test sample according to the weight, and performing intragastric administration for 1 time every day for 30 days continuously. After the test sample is given for the last time, various physical fatigue relieving function indexes are respectively measured.
TABLE 4 dose groupings
Figure BDA0001562278520000081
(1) Mouse weight bearing swimming test
After 30min of the last administration of the test sample, the weight of each mouse was weighed, the tail root of each mouse was loaded with 5% weight lead skin, and the mice were placed in a swimming chamber with a water depth of 30 + -1 cm and a water temperature of 25 + -1 deg.C for swimming, and the water was stirred occasionally to keep the four limbs of the mice in motion. The time(s) to death from the start of swimming was recorded.
TABLE 5 measurement of mouse weight swimming time
Figure BDA0001562278520000082
And (4) analyzing results: table 5 shows the comparison of swimming time with control group and coenzyme Q in the example group10The group, the perilla seed oil group and the buckwheat protein group are obviously prolonged, and the difference has statistical significance (P is less than 0.05).
(2) Liver glycogen assay (anthrone method)
Immediately after 30min from the last administration of the test sample, the test sample was sacrificed. Removing liver, rinsing with normal saline, drying with filter paper, accurately weighing 100mg liver, and detecting hepatic glycogen content by anthrone method.
TABLE 6 measurement of liver glycogen content in mice
Figure BDA0001562278520000083
Figure BDA0001562278520000091
And (4) analyzing results: table 6 shows that hepatic glycogen of example group is compared with control group, coenzyme Q10The group, the perilla seed oil group and the buckwheat protein group are obviously increased, and the difference has statistical significance (P is less than 0.05).
(3) Blood lactic acid assay
After the test substance is given to the mouse for 30min at the last time, the mouse is put into a swimming box with the water temperature of 30 ℃ and the water depth of 35cm without bearing a load, is taken out after swimming for 10min, 20ul of tail blood is immediately collected, is added into a test tube containing 40ul of hemolytic agent and is mixed evenly, and the blood lactic acid value is tested by a biosensor analyzer. In addition, the blood lactate level was measured before and after swimming at 20min rest in the same manner.
TABLE 7 mouse blood lactic acid content (mmol/L) and area under the curve
Figure BDA0001562278520000092
And (4) analyzing results: table 7 shows that the experimental group and the control group, coenzyme Q10The group, the perilla seed oil group and the buckwheat protein group are compared pairwise, and the difference has statistical significance (P is less than 0.05).
(4) Serum urea nitrogen determination
After the test substance is given to the mouse for 30min at the last time, the mouse is placed in water with the temperature of 30 ℃ for swimming for 90min, the mouse is rested for 60min, the eyeball is picked for blood collection, and the separated serum is measured by a full-automatic biochemical analyzer.
TABLE 8 measurement results of urea nitrogen content in mouse serum
Figure BDA0001562278520000093
And (4) analyzing results: table 8 shows that the serum urea nitrogen content of each experimental group is obviously lower than that of the control group, and the difference has statistical significance (P is less than 0.05).
2. Human body test eating test for assisting in reducing blood fat
The test adopts two control designs of self and group, and is included into 180 volunteer subjects meeting the standard, and randomly divided into experimental group and perilla seed oil group according to the requirement of double blind method (the preparation method is the same as example 2, and no coenzyme Q is used)10Buckwheat protein) and placebo groups, 60 per group, were subjected to human feeding trial studies. Experimental group for taking example 2 coenzyme Q after dinner10Compound soft capsule, 1 time daily, 2 capsules each time, is taken continuouslyIt was used for 30 days.
TABLE 9 test results
Figure BDA0001562278520000101
As a result: table 9 shows that the differences between the experimental group and the control group and the soft capsule group of perilla seed oil have statistical significance (P is less than 0.05).
TABLE 10 Long-term stability test data for the product of inventive example 2
Figure BDA0001562278520000102
Figure BDA0001562278520000111

Claims (6)

1. The soft capsule for relieving physical fatigue and assisting in reducing blood fat is characterized by comprising filling liquid and a rubber sheet, wherein the content is prepared from the following components in parts by weight:
coenzyme Q1030-50 parts of buckwheat protein, 10-20 parts of perilla seed oil, 300-500 parts of soybean oil and 25-40 parts of beeswax.
2. The soft capsule for relieving physical fatigue and assisting in reducing blood fat according to claim 1, which is characterized in that the capsule skin is prepared from the following components in parts by weight:
1-4 parts of cocoa shell color, 1-4 parts of titanium dioxide, 180-220 parts of gelatin, 60-90 parts of glycerol and 180-220 parts of purified water.
3. The soft capsule for relieving physical fatigue and assisting in reducing blood fat according to claim 2, which is characterized by being prepared from the following components in parts by weight:
coenzyme Q1037 parts of buckwheat protein, 15 parts of perilla seed oil, 6 parts of soybean oil 397 parts, 30 parts of beeswax, 2 parts of cocoa shell color, 2 parts of titanium dioxide and Mingming200 parts of glue, 80 parts of glycerol and 200 parts of purified water.
4. A method for preparing the soft capsule for relieving physical fatigue and assisting in reducing blood fat of claim 2 or 3, which is characterized by comprising the following steps:
mixing gelatin, glycerol, purified water, titanium dioxide and cocoa shell color to prepare a glue solution; then preparing oil wax solution from soybean oil and beeswax, adding coenzyme Q10Adding oil wax solution into buckwheat protein and perilla seed oil, grinding by colloid mill, vacuum-pumping under reduced pressure for degassing to obtain filling liquid, and making soft capsule from the filling liquid and the glue solution by pill press.
5. The preparation method of the soft capsule for relieving physical fatigue and assisting in reducing blood fat according to claim 4, which is characterized in that the preparation of the oily wax liquid comprises the following specific steps: weighing soybean oil, heating to 60-70 ℃, adding beeswax, keeping the temperature at 60-70 ℃, completely melting the beeswax, and uniformly stirring and mixing to obtain an oil wax liquid; the conditions for compression of the soft capsules were as follows: the temperature of the glue box is 50-60 ℃, the temperature of the heat preservation tank is 35-45 ℃, and the temperature of the spray body is 31-41 ℃.
6. The use of the composition of claim 1 in the preparation of a medicament or health food for relieving physical fatigue and assisting in reducing blood lipid.
CN201810085469.8A 2018-01-29 2018-01-29 Composition for relieving physical fatigue and assisting in reducing blood fat and soft capsule thereof Active CN108236714B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810085469.8A CN108236714B (en) 2018-01-29 2018-01-29 Composition for relieving physical fatigue and assisting in reducing blood fat and soft capsule thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810085469.8A CN108236714B (en) 2018-01-29 2018-01-29 Composition for relieving physical fatigue and assisting in reducing blood fat and soft capsule thereof

Publications (2)

Publication Number Publication Date
CN108236714A CN108236714A (en) 2018-07-03
CN108236714B true CN108236714B (en) 2021-09-10

Family

ID=62699700

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810085469.8A Active CN108236714B (en) 2018-01-29 2018-01-29 Composition for relieving physical fatigue and assisting in reducing blood fat and soft capsule thereof

Country Status (1)

Country Link
CN (1) CN108236714B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1817167A (en) * 2006-03-07 2006-08-16 山西大学 Extraction of buckwheat protein from buckwheat bran
CN104983791A (en) * 2015-06-18 2015-10-21 南京邦康生物技术有限公司 Health-care product containing coenzyme Q10 and preparation method thereof
CN106902150A (en) * 2017-03-16 2017-06-30 桦南仙紫食品科技有限公司 Co-Q10 purple perilla soft capsule prescription and preparation method

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1817167A (en) * 2006-03-07 2006-08-16 山西大学 Extraction of buckwheat protein from buckwheat bran
CN104983791A (en) * 2015-06-18 2015-10-21 南京邦康生物技术有限公司 Health-care product containing coenzyme Q10 and preparation method thereof
CN106902150A (en) * 2017-03-16 2017-06-30 桦南仙紫食品科技有限公司 Co-Q10 purple perilla soft capsule prescription and preparation method

Also Published As

Publication number Publication date
CN108236714A (en) 2018-07-03

Similar Documents

Publication Publication Date Title
CN101011561B (en) Modern traditional Chinese medicine oral preparation huanglianwendan decoction and production method thereof
CN101822749B (en) Medicinal preparation for curing hypertension and hyperlipaemia and preparation method thereof
CN108420854B (en) Antifatigue composition for improving endurance performance
CN104491350A (en) Health product capable of regulating health of heart and cerebral vessels and reducing risk of cardiovascular and cerebrovascular diseases
CN1814167A (en) Health-care for diabetes
CN107455625A (en) A kind of nutrient for plants beverage and its preparation technology with antifatigue weight losing function
CN105124347A (en) Moringa oleifera blood-glucose-reducing composition and preparation method thereof
CN103608024A (en) Pharmaceutical composition for controlling blood sugar, blood lipid and body weight
CN101664180B (en) Health-care nutritional complexing agent with health effect and preparation method thereof
WO2015190872A1 (en) Pharmaceutical composition containing spirulina maxima extract as active ingredient for treating and preventing obesity
CN104106828A (en) Solid beverage for reducing blood glucose
CN104352552A (en) Food, health care product or medicine composition
CN107095300A (en) A kind of biological nutrition compound composition of auxiliary treatment diabetes
CN116076710A (en) Rose herbal ferment with anti-aging and whitening functions and preparation method and application thereof
CN108236714B (en) Composition for relieving physical fatigue and assisting in reducing blood fat and soft capsule thereof
CN110237117A (en) A kind of soft capsule and preparation method thereof of Menopause anti-aging
CN107537028B (en) Formula for simultaneously assisting in reducing blood sugar and blood pressure and preparation method thereof
AU2012325600B2 (en) Pharmaceutical composition regulating blood fat and preparation process thereof
CN105101817A (en) Edible composition, preparation method therefor, and food product comprising the composition
CN114028509A (en) Medicinal and edible composition for soothing liver, strengthening spleen and promoting blood circulation and preparation method thereof
CN104256618B (en) A kind of hypoglycemic food, health products or pharmaceutical composition
CN104055115B (en) A kind of health products containing agate coffee, the stem of noble dendrobium and Panax Japonicus Var. Major and preparation method thereof
CN103798596B (en) Total nutrient formula food suitable for patients with cardiovascular and cerebrovascular diseases
CN105733880A (en) Composite hazelnut wine brewed from hazelnut meal
CN112089784A (en) Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diseases caused by atherosclerosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant